MedTrace Logo

Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids

NCT01332344 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5180

Last updated 2017-06-02

No results posted yet for this study

Summary

The objective of this study is to compare healthcare utilization and costs in asthma patients who receive fluticasone propionate/salmeterol combination 100mcg/50mcg ("FSC 100/50") or inhaled corticosteriods in typical clinical practice using a retrospective observational cohort study design of large managed care database.

Conditions

Interventions

DRUG

Fluticasone propionate/salmeterol combination

Asthma subjects newly prescribed fluticasone propionate/salmeterol combination

DRUG

Inhaled corticosteroids

asthma subjects newly prescribed inhaled corticosteroids in clinical practice

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-06-30
Completion
2010-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01332344 on ClinicalTrials.gov